UK's ImmuPharma jumps on clinical trial agreement for lupus study
06/02/2023 08:45
** Shares of ImmuPharma Plc IMM.L rise as much as 24% to
3.25p, stock top pct gainer across all London stocks .FTAS
** The specialist drug development firm says co and partner
Avion agree on an adaptive Phase 2/3 study for Lupus, an
immunity-related disease
** Says study set to start in second half of 2023, following
submission through the U.S. Food and Drug
Administration/Prescription Drug User Fee Act process
** Adds clinical programme also expected to be less costly
overall
** Including session's gains, stock has surged about 66% YTD
after slumping more than 72% in 2022
(Reporting by Aby Jose Koilparambil in Bengaluru)
((abyjose.koilparambil@thomsonreuters.com))